OPTIMUS: Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer
Study Details
Study Description
Brief Summary
The purpose of this study is to provide a go/no-go decision for a randomized expansion study by assessing the disease control rate (DCR) at 6 weeks for the combination of olaptesed pegol on top of pembrolizumab and (Arm 1) nanoliposomal irinotecan, 5-FU and leucovorin or (Arm 2) gemcitabine and nab-paclitaxel, to assess safety and tolerability and time-to-event endpoints.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Arm 1: olaptesed pegol + pembrolizumab + nanoliposomal irinotecan + 5-FU + LV
|
Drug: Olaptesed pegol
400 mg per week as continous infusion until progression or intolerable toxicity
Other Names:
|
| Experimental: Arm 2: olaptesed pegol + pembrolizumab + gemcitabine + nab-paclitaxel
|
Drug: Olaptesed pegol
400 mg per week as continous infusion until progression or intolerable toxicity
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Go/no-go decision for a randomized expansion study [until progression or intolerable toxicity to completion of 35 administrations (approximately 2 years) with pembrolizumab]
Assessment of the disease control rate (DCR) at 6 weeks for the combination of olaptesed pegol on top of pembrolizumab and (Arm 1) nanoliposomal irinotecan, 5-FU and leucovorin or (Arm 2) gemcitabine and nab-paclitaxel
Secondary Outcome Measures
- Safety and tolerability [until progression or intolerable toxicity to completion of 35 administrations (approximately 2 years) with pembrolizumab]
Safety and tolerability of olaptesed pegol pegol on top of pembrolizumab and (Arm 1) nanoliposomal irinotecan, 5-FU and leucovorin or (Arm 2) gemcitabine and nab-paclitaxel
- DCR at 12 weeks [until progression or intolerable toxicity to completion of 35 administrations (approximately 2 years) with pembrolizumab]
- Progression free survival (PFS) [until progression or intolerable toxicity to completion of 35 administrations (approximately 2 years) with pembrolizumab]
- Overall response rate (ORR) [until progression or intolerable toxicity to completion of 35 administrations (approximately 2 years) with pembrolizumab]
- median Overall survival (mOS) [until progression or intolerable toxicity to completion of 35 administrations (approximately 2 years) with pembrolizumab]
- Duration of response (DOR) [until progression or intolerable toxicity to completion of 35 administrations (approximately 2 years) with pembrolizumab]
- Time-to-best overall response (TBOR) [until progression or intolerable toxicity to completion of 35 administrations (approximately 2 years) with pembrolizumab]
- Time-to-next-anticancer-treatment (TTNT) [until progression or intolerable toxicity to completion of 35 administrations (approximately 2 years) with pembrolizumab]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patient with confirmed microsatellite-stable tumor pathology, if data available
-
Patient with histologically or cytologically confirmed primary metastatic adenocarcinoma of the pancreas, who
-
Arm 1: stopped first-line treatment with gemcitabine/nab-paclitaxel after documented objective radiographic progression OR
-
Arm 2: stopped first-line treatment with FOLFIRINOX or modified FOLFIRINOX after documented objective radiographic progression
-
Measurable disease based on RECIST 1.1 as determined by the investigational site
-
Estimated minimum life expectancy 3 months
-
Eastern Cooperative Oncology Group (ECOG) performance score 0 to 1
-
Adequate organ function laboratory values within the ranges specified: Serum albumin ≥ 3.0 g/dL; Hematological system: Hemoglobin (Hb) ≥ 9.0 g/dL or ≥5.6 mmol/L, Absolute neutrophil count (ANC) ≥ 1,500/mm³, Platelets ≥ 100,000/mm³; Renal system: Creatinine ≤ 1.5 x ULN OR eGFR ≥30 mL/min for patient with creatinine levels >1.5 × institutional ULN; Hepatic system: Total bilirubin ≤ 1.5 x ULN OR direct bilirubin ≤ULN for patients with total bilirubin levels >1.5 × ULN, ALT and AST ≤ 2.5 x ULN (≤5 × ULN for patients with liver metastases); Coagulation: INR OR PT ≤ 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants, aPTT ≤ 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
Exclusion Criteria:
-
Prior systemic anti-cancer therapy including investigational agents within 4 weeks or 5 half-lives, whichever is shorter, prior to treatment.
-
Patients must have recovered from all AEs due to previous therapies to ≤ Grade 1 or baseline. Patients with ≤ Grade 2 neuropathy may be eligible. Patients with endocrine-related AEs Grade ≤2 requiring treatment or hormone replacement may be eligible.
-
If the patient had major surgery, the patient must have recovered adequately from the procedure and/or any complications from the surgery prior to starting study intervention
-
Prior radiotherapy within 2 weeks of start of study treatment. Patients must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis.
-
Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137) and discontinued from that treatment due to a Grade 3 or higher irAE
-
Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug
-
Received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention. Administration of killed vaccines are allowed
-
Active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
-
History of (non-infectious) pneumonitis / interstitial lung disease that required steroids or current pneumonitis / interstitial lung disease
-
Active infection requiring systemic therapy
-
Known additional malignancy that is progressing or has required active treatment within the past 2 years.
-
Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
-
Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment
-
Previous allogeneic tissue/solid organ transplant
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- TME Pharma AG
- Merck Sharp & Dohme LLC
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SNOXA12C701
- 2021-001963-25
- Keynote-B01